CC-95251

DRUG2 trials

Sponsors

Celgene, Bristol-Myers Squibb

Conditions

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesNeoplasms

Phase 1

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

TerminatedNCT03783403

CelgeneNeoplasms

Start: 2019-03-01End: 2024-08-05Updated: 2024-09-19

A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes

TerminatedNCT05168202

Bristol-Myers SquibbLeukemia, Myeloid, Acute, Myelodysplastic Syndromes

Start: 2022-01-19End: 2024-07-30Updated: 2025-09-25

Related Papers

Discovery and Preclinical Activity of BMS-986351, an Antibody to SIRPα That Enhances Macrophage-mediated Tumor Phagocytosis When Combined with Opsonizing Antibodies

Cancer Research Communications2024-02-066 citations

S219: FIRST CLINICAL STUDY OF THE ANTI-SIGNAL REGULATORY PROTEIN-ALPHA (SIRPΑ) ANTIBODY CC-95251 COMBINED WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL)

HemaSphere2022-06-01

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Blood2021-11-0518 citations

Discovery and Preclinical Characterization of CC-95251, an Anti-SIRPα Antibody That Enhances Macrophage-Mediated Phagocytosis of Non-Hodgkin Lymphoma (NHL) Cells When Combined with Rituximab

Blood2021-11-059 citations